Results 131 to 140 of about 66,239 (358)

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

BJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui, Marlene Elmelund, Niels Klarskov   +2 more
wiley   +1 more source

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect

Frontiers in Pharmacology, 2016
We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, three months after switching anticoagulant from the vitamin K antagonist ...
Kuntheavy Ing Lorenzini, Youssef Daali, Pierre Fontana, Jules Desmeules, Caroline Flora Samer   +4 more
doaj   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

Stability-indicating method for the determination of Rivaroxaban and its degradation products using LC-MS and TLC [PDF]

, 2018
A validated stability indicating thin layer chromatographic (TLC) and liquid chromatography coupled with mass spectrometry LC/MS methods were developed to analyse Rivaroxaban and its degradation products.
Al-Lahham, Fida, Al-Mardini, Mohammad Amer, Arous, Basima, Ghazal, Heba   +3 more
core   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

New England Journal of Medicine, 2018
Background Heart failure is associated with activation of thrombin‐related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for ...
F. Zannad, S. Anker, W. Byra, J. Cleland, Minghuan Fu, M. Gheorghiade, C. Lam, M. Mehra, J. Neaton, C. Nessel, T. Spiro, D. V. van Veldhuisen, B. Greenberg   +12 more
semanticscholar   +1 more source

Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.

JAMA cardiology, 2020
Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD) experience an increased risk of major vascular events. There is limited information on what clinical features of symptomatic LE-PAD prognosticate major vascular ...
E. Kaplovitch, J. Eikelboom, L. Dyal, V. Aboyans, M. T. Abola, P. Verhamme, Á. Avezum, K. Fox, S. Berkowitz, S. Bangdiwala, S. Yusuf, Sonia S Anand   +11 more
semanticscholar   +1 more source

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis and cost-effectiveness analysis [PDF]

, 2017
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH):
Sterne, Jonathan Ac, Bodalia, Pritesh N, Bryden, Peter A, Davies, Philippa A, López-López, Jose A, Okoli, George N, Thom, Howard Hz, Caldwell, Deborah M, Dias, Sofia, Eaton, Diane, Higgins, Julian Pt, Hollingworth, William, Salisbury, Chris, Savović, Jelena, Sofat, Reecha, Stephens-Boal, Annya, Welton, Nicky J, Hingorani, Aroon D   +17 more
core   +3 more sources